Artificial intelligence (AI) and machine learning (ML) have potential to revolutionise cell and gene therapy (CGT), from patient recruitment to supply chain optimisation. Up to 90% of AI/ML models do not make it into production due to challenges in data handling and regulatory hurdles. CGT developers looking to adopt AI must ensure they are aware of these issues and address challenges relating to data availability, limitations in data access, algorithm validation and security.
Dashboards, automation on top of palliative care nurses’ wishlist
Aged care nurses in Australia have voiced their interest in improved and integrated technology solutions to provide streamlined end-of-life care, though they face challenges with
